logo
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, along with the rest of the management team, and other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Monday, July 21, 2025, in connection with its Frontiers in Brain Health R&D Day event being held today.
Herriot Tabuteau, MD, Chief Executive Officer of Axsome said, 'We are thrilled to ring NASDAQ's opening bell in connection with our Frontiers in Brain Health R&D Day today, showcasing our pioneering work across our pipeline of innovative, late-stage CNS product candidates, and commemorating the recent availability of SYMBRAVO® by prescription in the U.S. With our growing portfolio of differentiated on-market medicines, and our pipeline of potentially transformative investigational medicines, Axsome is defining the future of clinical practice in brain health to improve the lives of the millions of patients living with serious and difficult-to-treat CNS conditions.'
The opening bell ceremony will take place at the Nasdaq MarketSite located in Times Square, New York, NY. The live ceremonies will begin at 9:20 a.m. Eastern Time and can be viewed at
https://www.nasdaq.com/marketsite/bell-ringing-ceremony
.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain's biggest problems so patients and their loved ones can flourish. For more information, please visit us at
www.axsome.com
and follow us on
LinkedIn
and
X
.
Forward Looking Statements
Certain matters discussed in this press release are 'forward-looking statements'. The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company's SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company's efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company's ability to maintain and expand payer coverage; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund the Company's disclosed clinical trials, which assumes no material changes to the Company's currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company's ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application ('NDA') for any of the Company's current product candidates; the Company's ability to fund additional clinical trials to continue the advancement of the Company's product candidates; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration ('FDA') or other regulatory authority approval of, or other action with respect to, the Company's product candidates, including statements regarding the timing of any NDA submission; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company's ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products and product candidates, if approved; the Company's anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company's commercial launch of its other product candidates, if approved, and the potential impact on the Company's anticipated cash runway; the Company's ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com
Media:
Darren Opland
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
Nasdaq MarketSite Media Contact:
Sophia Weiss
(646) 483-6960
Sophia.weiss@nasdaq.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Here's 1 New Billion-Dollar Reason to Buy Solana And Never Look Back
Here's 1 New Billion-Dollar Reason to Buy Solana And Never Look Back

Yahoo

time23 minutes ago

  • Yahoo

Here's 1 New Billion-Dollar Reason to Buy Solana And Never Look Back

Key Points Asset managers are migrating commodities like gold bullion to blockchains. One such business just decided to move its gold holdings onto Solana. These assets are just the early movers in a mega-trend that will benefit the chain. 10 stocks we like better than Solana › Gold has always gravitated toward the world's deepest vaults, starting first with royal treasuries, then central banks, and now, apparently, blockchains. The latest flow is led by BioSig Technologies (NASDAQ: BSGM), which just said it would convert as much as $1.1 billion in physical gold bullion into crypto tokens on the Solana (CRYPTO: SOL) blockchain. For long-term investors, that single decision is one of the clearest signs yet that high-value, highly regulated commodities can, and will, live on Solana. If you have been waiting for a concrete, billion-dollar catalyst before adding to your Solana stack, this might be it. Here's why. This chain is getting gilded On July 7, BioSig inked a financing deal worth as much as $1.1 billion to build a commodities tokenization platform, starting with gold. A bit later, it was confirmed that the company would issue those gold-backed tokens on Solana's chain. That single project is enormous relative to Solana's current real-world asset (RWA) footprint; all tokenized real-world assets on Solana total about $536 million today. If the full $1.1 billion in gold bullion shows up on-chain, the value of RWAs hosted by the network could thus jump by roughly threefold overnight. And that would certainly have a very positive impact on the coin's price. But why did this business choose Solana specifically? In short, it was the chain's low fees, which are typically fractions of a cent, and its lightning-fast transaction processing times, both of which matter when every token represents a bar of gold worth tens of thousands of dollars. The chain's average throughput is about 1,671 transactions per second (TPS) as of noon on July 24, with its development roadmap aiming much higher via the upcoming Firedancer upgrade. Those performance stats will help treasurers move bullion-backed tokens (or any other kind of token) quickly without worrying about network congestion or fee spikes. In other words, BioSig's bullion is finding a new home, and in doing so it is endorsing Solana's technical design as fit for purpose in the ultra-conservative world of precious metals custody. That kind of validation is hard to buy, and even harder to ignore. The tokenization segment is the future Real-world-asset tokenization is no niche experiment, and it's likely going to be a huge driver of growth for Solana, as well as perhaps a few of its competitors. Boston Consulting Group (BCG) projects that just over $16 trillion of illiquid assets could be tokenized on-chain by 2030. Today, just $25 billion is tokenized across all chains, leaving a colossal runway for expansion. Importantly, the ultimate winners of the tokenization trend are not decided yet, though there are a handful of early leaders, of which Solana is one. The chain is currently experiencing the fastest growth of tokenized stocks in the entire crypto sector, though it only hosts just over $96 million in that category today. Add BioSig's gold tokens to the mix, and Solana suddenly hosts a diversified, multibillion-dollar basket of tokenized U.S. Treasury bills, cash, and commodities. Network fundamentals are already moving in tandem with inflows of new assets, as the chain generated $271 million in network revenue in the second quarter of 2025, topping every other chain for the third straight period. Furthermore, rising revenue signals growing demand for block space, which is almost always a precursor to sustained token appreciation. Of course, nothing travels in a straight line. Other blockchains are vying for the same tokenization pie, and regulators still have to hammer out commodity-token rules in major markets. Yet Solana's design, coupled with a thriving ecosystem of compliance-ready service providers, means it can integrate know-your-customer (KYC) layers without rewriting its core code, which is a valuable capability, especially compared to some of the other players in the sector. Assuming regulators approve genuine commodity tokens at some point -- and early signals look promising -- Solana's head start could solidify into an actual economic moat. But don't bet on that outcome just yet because there are still a lot of issues to resolve. For investors, the takeaway is clear. Each fresh billion of real-world assets onboarded to Solana reinforces part of the investment thesis for the coin, namely that the chain that settles those RWAs fastest and cheapest will gain in value. This is a good time to be buying this coin. Lastly, recognize that BioSig's gold is likely the opening salvo in a wider commodities rush, not an isolated event. So stay tuned. Should you buy stock in Solana right now? Before you buy stock in Solana, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Solana wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Alex Carchidi has positions in Solana. The Motley Fool has positions in and recommends Solana. The Motley Fool has a disclosure policy. Here's 1 New Billion-Dollar Reason to Buy Solana And Never Look Back was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Do Mission Produce's (NASDAQ:AVO) Earnings Warrant Your Attention?
Do Mission Produce's (NASDAQ:AVO) Earnings Warrant Your Attention?

Yahoo

time23 minutes ago

  • Yahoo

Do Mission Produce's (NASDAQ:AVO) Earnings Warrant Your Attention?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away. Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Mission Produce (NASDAQ:AVO). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Mission Produce's Earnings Per Share Are Growing The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Mission Produce managed to grow EPS by 15% per year, over three years. That growth rate is fairly good, assuming the company can keep it up. One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. EBIT margins for Mission Produce remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 29% to US$1.4b. That's a real positive. The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers. See our latest analysis for Mission Produce You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Mission Produce's future profits. Are Mission Produce Insiders Aligned With All Shareholders? It's pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. Shareholders will be pleased by the fact that insiders own Mission Produce shares worth a considerable sum. Indeed, they have a considerable amount of wealth invested in it, currently valued at US$280m. That equates to 33% of the company, making insiders powerful and aligned with other shareholders. Very encouraging. Should You Add Mission Produce To Your Watchlist? As previously touched on, Mission Produce is a growing business, which is encouraging. For those who are looking for a little more than this, the high level of insider ownership enhances our enthusiasm for this growth. The combination definitely favoured by investors so consider keeping the company on a watchlist. While we've looked at the quality of the earnings, we haven't yet done any work to value the stock. So if you like to buy cheap, you may want to check if Mission Produce is trading on a high P/E or a low P/E, relative to its industry. While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in the US with promising growth potential and insider confidence. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Macy's, Inc. Announces Early Tender Results and Upsizing of Debt Tender Offer
Macy's, Inc. Announces Early Tender Results and Upsizing of Debt Tender Offer

Business Wire

time24 minutes ago

  • Business Wire

Macy's, Inc. Announces Early Tender Results and Upsizing of Debt Tender Offer

NEW YORK--(BUSINESS WIRE)--Macy's, Inc. (NYSE:M) (the 'Company') today announced the early tender results of the previously announced cash tender offer (the 'Tender Offer') by its wholly owned subsidiary, Macy's Retail Holdings, LLC (the 'Issuer'), to purchase up to an aggregate principal amount of its outstanding notes and debentures listed in the table below (collectively, the 'Notes') for an amended combined aggregate purchase price of $250 million (excluding accrued and unpaid interest, which also will be paid to, but excluding, the applicable Settlement Date and excluding fees and expenses related to the Tender Offer) (the 'Maximum Tender Offer Amount'), in the order of priority shown in the table. The Company has amended the terms of the Tender Offer to increase the Maximum Tender Offer Amount from $175 million to $250 million. The terms and conditions of the Tender Offer are described in an Offer to Purchase dated July 14, 2025, as modified by this release, the 'Offer to Purchase'. The Tender Offer is subject to the satisfaction of certain conditions as set forth in the Offer to Purchase, including the Financing Condition (as described herein). Capitalized terms used in this press release and not defined herein have the meanings given to them in the Offer to Purchase. The aggregate principal amount of Notes of each series that were validly tendered and not validly withdrawn as of 5:00 p.m., New York City time, on July 25, 2025 (the 'Early Tender Date'), as reported by the tender agent, and the aggregate principal amount of each series of Notes the Issuer will accept for purchase on the Early Settlement Date (as defined below) are specified in the table below. The amount of each series of Notes the Issuer will accept for purchase on the Early Settlement Date (as defined below) will be subject to the applicable proration factor specified in the table below, as determined in accordance with the acceptance priority levels and the proration procedures described in the Offer to Purchase and in this press release. CUSIP Numbers Title of Security Aggregate Principal Amount Outstanding Acceptance Priority Level Principal Amount Tendered on or Prior to the Early Tender Date Principal Amount Accepted on the Early Settlement Date Total Tender Offer Consideration(1) Approximate Proration Factor(2) 55616XAB3 6.790% Senior Debentures due 2027 $60,677,000 1 $26,674,000 $26,674,000 $1,027.50 100.00% 577778BK8 7.875% Senior Debentures due 2030 $5,212,000 2 $254,000 $254,000 $1,020.00 100.00% 55617LAG7 55617LAH5 U5562LAD1 7.875% Senior Exchanged Debentures due 2030 $4,676,000 2 $126,000 $126,000 $1,020.00 100.00% 55617LAQ5 U5562LAH2 5.875% Senior Notes due 2030 $425,000,000 3 $329,918,000 $223,883,000 $992.50 67.93% Expand (1) Per $1,000 principal amount of Notes validly tendered on or before the Early Tender Date, not validly withdrawn and accepted for purchase for each Series. Includes the Early Tender Premium of $30.00 per $1,000 principal amount of Notes and excludes accrued and unpaid interest to, but, excluding, the Early Settlement Date, which will also be paid on the Early Settlement Date. (2) Rounded to the nearest tenth of a percentage point for presentation purposes. Expand The Tender Offer is subject to, and conditioned upon, the satisfaction or waiver of certain conditions described in the Offer to Purchase, including the completion of the Issuer's separately announced offering of new senior notes (the 'New Notes Offering') on terms satisfactory to the Issuer, in its sole discretion, prior to or on the Early Settlement Date (such condition, the 'Financing Condition') and certain general conditions, in each case as described in more detail in the Offer to Purchase. The Tender Offer is not conditioned upon any minimum amount of Notes being tendered, and the Tender Offer may be amended, extended or terminated. Although the Tender Offer is scheduled to expire at 5:00 p.m., New York City time, on August 11, 2025 (the 'Expiration Date'), because holders of Notes subject to the Tender Offer validly tendered and did not validly withdraw Notes on or before the Early Tender Date in an amount that exceeds the Maximum Tender Offer Amount, the Issuer does not expect to accept for purchase any tenders of Notes after the Early Tender Date. The settlement date for Notes validly tendered and not validly withdrawn on or prior to the Early Tender Date and accepted for purchase will be July 29, 2025 (the 'Early Settlement Date'), subject to the satisfaction or waiver of all conditions to the Tender Offer described in the Offer to Purchase. Subject to the terms and conditions of the Tender Offer, holders who tendered their Notes on or prior to the Early Tender Date and whose Notes are accepted for purchase will receive the applicable total tender offer consideration set forth in the table above for each $1,000 principal amount of Notes accepted for purchase pursuant to the Tender Offer (the 'Total Tender Offer Consideration'), which includes an early tender premium of $30.00 per $1,000 principal amount of Notes. In addition to the applicable Total Tender Offer Consideration, all holders of Notes accepted for purchase on the Early Settlement Date will receive accrued and unpaid interest on their Notes purchased from the last interest payment date with respect to such Notes up to, but not including, the Early Settlement Date. The total principal amount of Notes validly tendered and not validly withdrawn as of the Early Tender Date has an aggregate purchase price exceeding the Maximum Tender Offer Amount. As a result, and based on the terms and conditions of the Tender Offer: all of the 6.790% Senior Debentures due 2027 that were tendered as of the Early Tender Date will be accepted for purchase on the Early Settlement Date; all of the 7.875% Senior Debentures due 2030 that were tendered as of the Early Tender Date will be accepted for purchase on the Early Settlement Date; all of the 7.875% Senior Exchanged Debentures due 2030 that were tendered as of the Early Tender Date will be accepted for purchase on the Early Settlement Date; $223,883,000 aggregate principal amount of the 5.875% Senior Notes due 2030 that were tendered as of the Early Tender Date will be accepted for purchase on the Early Settlement Date; and no Notes tendered after the Early Tender Date and prior to the Expiration Date (as defined below) will be accepted for purchase in the Tender Offer. Any Notes tendered but not accepted for purchase in the Tender Offer will be promptly credited to the account of the registered holder of such Notes with The Depository Trust Company and otherwise returned in accordance with the Offer to Purchase. The Issuer intends to use proceeds from the New Notes Offering, together with cash on hand, to (i) purchase the Notes subject to the Tender Offer, (ii) redeem approximately $587 million of certain of its existing outstanding senior notes and debentures and (iii) pay fees, premium and expenses in connection therewith. Wells Fargo Securities and US Bancorp are the Lead Dealer Managers for the Tender Offer. Global Bondholder Services Corporation is acting as Tender Agent and Information Agent. Persons with questions regarding the Tender Offer should contact Wells Fargo Securities at (collect) (704) 410-4759, (toll-free) (866) 309-6316 or by email to liabilitymanagement@ and US Bancorp at (collect) (917) 558-2756, (toll-free) (800) 479-3441 or by email to liabilitymanagement@ Any questions regarding the tendering of Notes should be directed to Global Bondholder Services Corporation at (toll-free) (855) 654-2014, (for banks and brokers) (212) 430-3774 or by email to contact@ This press release is neither an offer to purchase nor a solicitation of an offer to sell the Notes. Further, nothing contained herein shall constitute a notice of redemption of the Notes or any other securities. The Tender Offer is being made only by the Offer to Purchase and the information in this press release is qualified by reference to the Offer to Purchase. None of the Company or its affiliates, their respective boards of directors, the Dealer Managers, the Tender Agent, the Information Agent or the trustees with respect to any Notes is making any recommendation as to whether holders should tender any Notes in response to the Tender Offer, and neither the Company nor any such other person has authorized any person to make any such recommendation. Holders must make their own decision as to whether to tender any of their Notes, and, if so, the principal amount of Notes to tender. Any securities issued pursuant to New Notes Offering will not be registered under the Securities Act of 1933, as amended (the 'Securities Act'), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. This press release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities that may be issued pursuant to the New Notes Offering. About Macy's, Inc. Macy's, Inc. (NYSE: M) is a trusted source for quality brands through our iconic nameplates – Macy's, Bloomingdale's and Bluemercury. Headquartered in New York City, our comprehensive digital and nationwide footprint empowers us to deliver a seamless shopping experience for our customers. Forward-Looking Statements All statements regarding the closing of the Tender Offer, the New Notes Offering and satisfaction of the related closing conditions that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results could differ materially from those expressed in or implied by the forward-looking statements contained in this release because of a variety of factors, including, but not limited to, general market conditions which might affect the Tender Offer and any concurrent financing transaction, and other factors identified in documents filed by the Company with the Securities and Exchange Commission, including under the captions 'Forward-Looking Statements' and 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended February 1, 2025 and the Company's Quarterly Report on Form 10-Q for the quarterly period ended May 3, 2025. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store